Botulinum Toxin A Merz - Biotech, Pharma and Life Science Channel

09:43 EDT 18th September 2014 | BioPortfolio

PubMed Articles [709 Associated PubMed Articles listed on BioPortfolio]

Superhydrophobic-oleophobic Ag Nanowire Platform: An Analyte-concentrating and Quantitative Aqueous and Organic Toxin SERS Sensor.

The ultratrace detection and quantification of toxins in both water and organic liquids remains a challenge due to the random spreading and dilution of liquids on substrate-based sensors, especially f...

Algal chloroplast produced camelid VH H antitoxins are capable of neutralizing botulinum neurotoxin.

We have produced three antitoxins consisting of the variable domains of camelid heavy chain-only antibodies (VH H) by expressing the genes in the chloroplast of green algae. These antitoxins accumulat...

Doubling the cross-linking interface of a rationally-designed beta roll peptide for calcium-dependent proteinaceous hydrogel formation.

We have rationally engineered a stimulus-responsive cross-linking domain based on a repeats-in-toxin (RTX) peptide to enable calcium-dependent formation of supramolecular hydrogel networks. The peptid...

Characterization of variants of the pore-forming toxin ClyA from Escherichia coli controlled by a redox switch.

The α-pore-forming toxin Cytolysin A (ClyA) is responsible for the hemolytic phenotype of several Escherichia coli and Salmonella enterica strains. ClyA is a soluble, 34 kDa monomer that assembles in...

Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.

To assess the relative cost-effectiveness of two therapeutic strategies: one starting with sacral neuromodulation (SNM) versus one starting with Botulinum toxin A (BTX-A) for the management of refract...

Inactivation of the Pore-Forming Toxin Sticholysin I by Peroxynitrite: Protection by Cys Groups Incorporated in the Toxin.

Sea anemones synthesize a variety of toxic peptides and proteins of biological interest. The Caribbean Sea anemone Stichodactyla helianthus, produces two pore-forming toxins, Sticholysin I (St I) and ...

View From the Front Lines: An Emergency Medicine Perspective on Clostridial Infections in Injection Drug Users.

Injection drug use (IDU), specifically non-intravenous "skin-popping" of heroin, seems to provide optimal conditions for Clostridial infection and toxin production. IDU is therefore a major risk facto...

C. Difficile-induced colitis in mice is independent of leukotrienes.

Clostridium difficile is the major cause of antibiotic-associated diarrhea and pseudomembranous colitis in healthcare settings. However, the host factors involved in the intestinal inflammatory respon...

Proteomic Evidences for Rex Regulation of Metabolism in Toxin-Producing Bacillus cereus ATCC 14579.

The facultative anaerobe, Bacillus cereus, causes diarrheal diseases in humans. Its ability to deal with oxygen availability is recognized to be critical for pathogenesis. The B. cereus genome compris...

Mild method for succinimide hydrolysis on ADCs: Impact on ADC potency, stability, exposure, and efficacy.

The stability of the connection between the antibody and the toxin can have a profound impact on ADC safety and efficacy. There has been increasing evidence in recent years that maleimide-based ADCs a...

News Articles [201 Associated News Articles listed on BioPortfolio]

ACP Releases New Recommendations For Treating Urinary Incontinence In Women

Steve Majewski, American College of Physicians Kegel exercises, bladder training, and weight loss are among recommendations in ACP’s new evidence-based guideline Kegel exercises to strengthen pelv...

Response Biomedical Corp. Announces Management Changes

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/16/14 -- Response Biomedical Corp. ("Response" or "the Company") (TSX: RBM)(OTCBB: RPBIF) announced today a series of management changes. Jeffrey P...

Molecular Templates Announces Completion of $12M Series C Financing

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapies, announced today that it has expanded its seri...

Dystonia - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Dystonia - Pipeline Review, H2 2014 is a new report from Global Markets Direct published on 2014-09-09. This 41-page report is available in PDF from $...

Noninvasive Face Lift Procedures On the Rise Among Older Generation

Dr. Kimberly Butterwick comments on the rising trend of noninvasive, natural-looking cosmetic procedures among men and women over age 55. San Diego, CA (PRWEB) September 12, 2014 According to an arti...

In Light of Self-Improvement Month, Corpus Christi, TX Dentist, Dr. Tilman Richards Recommends Laser Periodontal Disease Treatment for Patients Suffering from Gum Disease

In honor of Self-Improvement Month this September, Corpus Christi, TX dentist Dr. Tilman Richards educates patients with gum disease about why they should seek treatment for this progressive condition...

Botulinum Toxin (aka Botox) to Treat Depression? 3 Independent Studies Prove It’s Worth A Shot

Leading Researchers on Botox for Depression, Including Dr. Eric Finzi, Dr. Alex Wollmer, Dr. Kruger Tillmann and Dr. Michelle Magid, to Present Data from Clinical Studies at the XVI World Congress of ...

New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®

ANNAPOLIS, Md., Sept. 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were presented at th...

Center Director of Omni Eye Surgery in New York City Describes a Promising New Product for the Management of Eyelid Disease in News Publication

NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrot...

Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program

ROCKVILLE, Md., Sept. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific path...

Events [0 Results]

None

Companies [7 Associated Companies listed on BioPortfolio]

Merz North America, Inc.

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S...

Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurology in the U.S. and Canad...

Merz, Inc.

Merz, Inc. is a focused specialty healthcare company that is responsible for developing and commercializing innovative products and solutions in neurology, medical aesthetics, and...

Pharmaleads

Pharmaleads is a research company focussed on the custom design of substrates and inhibitors of zinc metallopeptidases and proteases. Pharmaleads has already developed molecules for ECE, NEP, ACE, APN...

Molecular Templates

Molecular Templates is a biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics using its novel Engineered Toxin Bodies (ETB) platfor...

Merz Aesthetics

Merz Aesthetics, the new business unit of Merz Pharma Group, is a leader in the global aesthetic medicine market. With a 100-year history of compassion and innovation in healthcare, Merz Aesthetics i...

DentaSpa

DentaSpa™ is one of the nation’s leading Botulinum Toxin, dermal fillers and injectables business education companies tailored exclusively for dental practitioners. Dent...

Clinical Trials [199 Associated Clinical Trials listed on BioPortfolio]

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are chronic conditions affecting approximately 1.4 million Americans. The burden of Clostridium dif...

Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating

The objective of this study is to determine if Myobloc significantly decreases prosthesis-associated symptomatic sweating in amputees when compared to a saline solution placebo. The study ...

Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients

The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in spinal cord injury patients.

Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole

The investigators propose a new therapeutic approach by injecting Botulinum Toxin Type A (BTA) to the oblique and transverse heads of adductor muscle of the great toe. BTA works by binding...

The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction

Breast reconstruction is a common procedure with over 86,000 breast reconstruction procedures performed in the United States in 2009. This is a 1.5-fold increase since 2007. Of these breas...

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subje...

Botulinum Toxin for the Treatment of Involuntary Movement Disorders

Botulism is a severe form of food poisoning caused by bacteria. This bacteria produces several toxins one of which is botulinum toxin A. This toxin causes the symptoms of food poisoning....

Amlodipine Plus Botulinum Toxin for Focal Dystonia

Objective: To determine if the calcium channel blockers, amlodipine can augment the effect of botulinum toxin injections in the treatment of focal dystonia. Study Population: 20 patien...

Motor Training to Treat Hand Dystonia

This study will evaluate the effect of motor training on focal hand dystonia in people with writer's cramp and will examine whether this training affects excitability of the motor cortex o...

Videos

Heidi Waldorf

THIS SUMMER, ASCLERA HELPS WOMEN TAKE A STAND AGAINST SPIDER VEINS Merz Aesthetics and Asclera®(polidocanol) Empowers Women to Not Only Look and Feel Good, b...

Medical and Biotech [MESH] Definitions

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type C which is neurotoxic to ANIMALS, especially CATTLE, but not humans. It causes dissociation of ACTIN FILAMENTS.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type D which is neurotoxic to ANIMALS, especially CATTLE, but not humans.

Subtype of CLOSTRIDIUM BOTULINUM that produces BOTULINUM TOXIN TYPE A which is neurotoxic to humans and animals.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type B which is neurotoxic to humans and animals.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type E which is neurotoxic to humans and animals.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Botulinum Toxin A Merz market research data and corporate reports here

Channels Quicklinks